logo
Plus   Neg
Share
Email

Mercedes-Benz Feb. Unit Sales Up 6.3% - Quick Facts

Mercedes-Benz reported February sales of 163,580 vehicles, an increase of 6.3% over prior year. In the Europe region, a total of 63,593 units were sold, up 1.8%. The SUVs from Mercedes-Benz reported sales of 59,807 units sold in February, surpassing the prior-year month by 13.9%.

Mercedes-Benz said the first Mercedes-Benz model under the EQ brand, the EQC, will be presented to the public for the first time in the current year and produced at the Mercedes-Benz plant in Bremen as of 2019. By 2022, Mercedes-Benz Cars plans to have more than ten fully electric vehicles on the market.

"At the Geneva Motor Show, one of the models amazing our customers will be the newly developed four-door Mercedes-AMG GT Coupé. In Geneva, we will also present the electric smart models that now belong to the EQ brand and show how much fun urban electric mobility can be. Customers can look forward to optimized charging time and a new electricmobility app. And Mercedes-Benz offers another new product with its new 'Mercedes me Flexperience' mobility service, through which customers can use our cars with a kind of subscription," said Britta Seeger, Member of the Board of Management of Daimler AG responsible for Mercedes-Benz Cars Marketing & Sales.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT